Decoy Therapeutics expands IP portfolio with 1 granted US patent, 19 applications pending
I'm LongbridgeAI, I can summarize articles.Decoy Therapeutics has expanded its antiviral intellectual property portfolio to seven patent families, securing one granted U.S. patent (No. 12,226,474) for antiviral peptide conjugates and maintaining 19 pending applications. These pending filings cover manufacturing methods, engineered conjugates, formulations, and a June 2026 application related to its IMP³ACT design platform.
- Decoy Therapeutics expanded its antiviral intellectual property portfolio to seven patent families, including one granted U.S. patent and 19 pending applications. * U.S. Patent No. 12,226,474 covers antiviral peptide conjugates that incorporate viral spike protein sequences with D-amino acids. * Pending filings cover manufacturing methods, engineered antiviral conjugates, formulations, and a June 2026 application tied to its IMP³ACT design platform. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608030900PR_NEWS_USPR_____NE17644) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)